Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 15,000 shares of the business's stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $61.93, for a total value of $928,950.00. Following the sale, the executive vice president owned 50,440 shares in the company, valued at $3,123,749.20. The trade was a 22.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Andrew Callos also recently made the following trade(s):
- On Monday, February 2nd, Andrew Callos sold 886 shares of Cytokinetics stock. The shares were sold at an average price of $62.10, for a total transaction of $55,020.60.
- On Monday, January 5th, Andrew Callos sold 15,000 shares of Cytokinetics stock. The stock was sold at an average price of $60.28, for a total transaction of $904,200.00.
- On Friday, January 2nd, Andrew Callos sold 1,798 shares of Cytokinetics stock. The shares were sold at an average price of $62.62, for a total value of $112,590.76.
- On Monday, December 29th, Andrew Callos sold 1,809 shares of Cytokinetics stock. The stock was sold at an average price of $62.44, for a total value of $112,953.96.
- On Monday, December 8th, Andrew Callos sold 1,042 shares of Cytokinetics stock. The shares were sold at an average price of $65.96, for a total value of $68,730.32.
- On Friday, December 5th, Andrew Callos sold 52,486 shares of Cytokinetics stock. The stock was sold at an average price of $65.95, for a total value of $3,461,451.70.
Cytokinetics Stock Down 5.2%
Shares of NASDAQ CYTK opened at $60.24 on Friday. Cytokinetics, Incorporated has a 52 week low of $29.31 and a 52 week high of $70.98. The business's 50 day moving average price is $63.47 and its 200 day moving average price is $55.32. The firm has a market cap of $7.37 billion, a P/E ratio of -9.58 and a beta of 0.54.
Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.59) by $0.05. The business had revenue of $1.94 million for the quarter, compared to analysts' expectations of $6.05 million. The business's quarterly revenue was up 318.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.36) earnings per share. As a group, research analysts expect that Cytokinetics, Incorporated will post -5.24 earnings per share for the current year.
Hedge Funds Weigh In On Cytokinetics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in shares of Cytokinetics by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 12,048,131 shares of the biopharmaceutical company's stock worth $765,538,000 after purchasing an additional 191,336 shares in the last quarter. Deep Track Capital LP boosted its holdings in Cytokinetics by 17.8% in the 3rd quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company's stock worth $236,328,000 after buying an additional 650,000 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Cytokinetics by 1.9% during the second quarter. Geode Capital Management LLC now owns 2,994,445 shares of the biopharmaceutical company's stock worth $98,948,000 after purchasing an additional 56,961 shares in the last quarter. Vestal Point Capital LP boosted its stake in Cytokinetics by 14.8% during the 2nd quarter. Vestal Point Capital LP now owns 2,975,000 shares of the biopharmaceutical company's stock worth $98,294,000 after purchasing an additional 384,469 shares during the last quarter. Finally, Woodline Partners LP boosted its position in Cytokinetics by 676.1% during the third quarter. Woodline Partners LP now owns 1,647,725 shares of the biopharmaceutical company's stock worth $90,559,000 after acquiring an additional 1,435,422 shares during the last quarter.
Wall Street Analysts Forecast Growth
Several research firms recently commented on CYTK. Citigroup reaffirmed a "market outperform" rating on shares of Cytokinetics in a report on Monday, December 22nd. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Cytokinetics in a research note on Tuesday, October 21st. Jefferies Financial Group reiterated a "buy" rating and issued a $90.00 target price on shares of Cytokinetics in a research note on Friday, January 9th. JPMorgan Chase & Co. raised their price target on shares of Cytokinetics from $70.00 to $74.00 and gave the company an "overweight" rating in a research report on Tuesday, January 20th. Finally, Wall Street Zen cut shares of Cytokinetics from a "hold" rating to a "sell" rating in a report on Saturday, November 8th. Seventeen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $87.42.
Check Out Our Latest Analysis on Cytokinetics
Cytokinetics Company Profile
(
Get Free Report)
Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.
The company's most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
